On 23 August 2017, orphan designation (EU/3/17/1901) was granted by the European Commission to Mayne Pharma UK Limited, United Kingdom, for itraconazole for the treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome).
The sponsorship was transferred to Voisin Consulting S.A.R.L., France, in February 2019.
In October 2021, Voisin Consulting S.A.R.L. changed name to Voisin Consulting Life Sciences.
Treatment of naevoid basal-cell carcinoma syndrome (Gorlin syndrome)
|Orphan designation status||
|EU designation number||
|Date of designation||
Review of designation
|July 2023||Please note that this product was withdrawn from the Union Register of orphan medicinal products in July 2023 on request of the Sponsor.|
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: